Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, GE Healthcare Forge Alliance for Hepatic Diseases
November 12, 2014
- Ethical Drug Sales Down 0.2% in September Owing to Long-Listed Drug Sales Decline: Crecon Report
November 12, 2014
- BIKEN Begins Clinical Trial of Varicella Vaccine for Herpes Zoster
November 12, 2014
- Dermatology Firm Maruho Eyes US Product Rollout in Next 3 Years
November 12, 2014
- Santen Extending Geographic Reach in Europe after Merck Asset Transfer
November 11, 2014
- Kowa Looks to Triple Eye Drug Business with Glanatec
November 11, 2014
- Germany Designates Eisai’s Antiepileptic Drug Fycompa as Reference Price Drug
November 11, 2014
- AstraZeneca Taps Foreign Doctors to Speak on Forxiga Use Abroad
November 11, 2014
- Nichi-Iko Aims for 300 Million Yen Second Half Sales for Generics Launched in December
November 10, 2014
- Takeda Files Suit in US Claiming Infringement of Its Patents for Gout Treatment Colcrys
November 10, 2014
- MTPC, J&J Collaborate to Promote Educational Activities for Diabetes
November 10, 2014
- Feburic Grabs Top Slot for GP Market in September “Mind Share” Ranking
November 10, 2014
- Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market
November 10, 2014
- Bayer, Kyoto Univ. to Hold First Collaborative Meeting by March
November 7, 2014
- Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales
November 7, 2014
- Ono to Copromote Opdivo with Bristol-Myers in Japan: President
November 7, 2014
- Trebananib Fails to Demonstrate Improvement in OS in PIII Study for Recurrent Ovarian Cancer: Takeda
November 7, 2014
- Toray Medical Files Nalfurafine for Pruritus Associated with Chronic Hepatic Disease
November 7, 2014
- Daiichi Sankyo to Cut Japan Jobs to Brace for Olmetec Patent Expiry
November 6, 2014
- Lorcaserin Confirms POC as Potential Smoking Cessation Aid in PII Study in US: Eisai
November 6, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…